


## Pathway for the pharmacological management of co-morbid insomnia in adults

Note: Melatonin, trazodone, mirtazapine and quetiapine are IMOC Amber 2 category – initiation by the sleep centre followed by maintenance prescribing in primary care. GPs are not expected to initiate these treatments but may be asked to take on prescribing in line with IMOC recommendations. Doxepin, agomelatine and vortioxetine are IMOC RED category (hospital only) – initiation and ongoing prescribing will be by the sleep service.



## Pathway for the pharmacological management of co-morbid insomnia in adults

Note: Melatonin, trazodone, mirtazapine and quetiapine are IMOC Amber 2 category – initiation by the sleep centre followed by maintenance prescribing in primary care. GPs are not expected to initiate these treatments but may be asked to take on prescribing in line with IMOC recommendations. Doxepin, agomelatine and vortioxetine are IMOC RED category (hospital only) – initiation and ongoing prescribing will be by the sleep service.

## Appendix 1 – Understanding the condition

### Sleep Foundation

Sleeping problems often have a bidirectional relationship with other health issues.

**Co-morbid insomnia** or secondary insomnia is a sleep disorder believed to arise as a result of another condition such as anxiety, depression, sleep apnoea, gastroesophageal reflux disease (GERD), or physical pain.

### **Acute Insomnia**

Acute insomnia otherwise known as short-term insomnia is a brief episode of difficulty sleeping.

It may be caused by a stressful life event such as a bereavement, global pandemic or a major job or relationship change.

Acute insomnia tends to last for less than three months.

However, it can be persistent and become chronic insomnia.

### **Chronic Insomnia**

Chronic insomnia is a long-term pattern of difficulty sleeping.

Insomnia is considered chronic if a person has trouble falling asleep or staying asleep at least three nights per week for three months or longer.

Like acute insomnia, it may be linked to stressful situations, but it may also be related to irregular sleep schedules, poor sleep hygiene, other sleep disorders etc.

## Pathway for the pharmacological management of co-morbid insomnia in adults

Note: Melatonin, trazodone, mirtazapine and quetiapine are IMOC Amber 2 category – initiation by the sleep centre followed by maintenance prescribing in primary care. GPs are not expected to initiate these treatments but may be asked to take on prescribing in line with IMOC recommendations. Doxepin, agomelatine and vortioxetine are IMOC RED category (hospital only) – initiation and ongoing prescribing will be by the sleep service.

## Appendix 2 – Non-pharmacological Management

### Lifestyle optimisation measures

- **Stimulus control**
  - Bed/bedroom use only for sleep, sex and getting dressed (not reading, resting, phone, watching TV etc.)
  - Get out of bed if not sleeping after 15-20 min (especially if agitated)
- **Sleep scheduling**
  - Limit time in bed to time actual average total sleep time (best achieved via sleep diaries)
  - Avoiding daytime and evening naps
  - Getting into bed only when sleepy tired
  - Getting up at the same time every day, including weekends
- **Additional**
  - Avoid caffeine after 12pm; switch to decaffeinated drinks
  - Avoid alcohol, at the very least in the 2 hours before bed
  - Daily exercise, ideally outside to gain exposure to natural day light
  - Other sleep hygiene advice via the [Sleep Foundation](#)

### Naps

- Discouraged because they reduce sleep drive.
- If naps cannot be avoided, then try to limit them to 20 minutes (setting an alarm), and ideally not in the 5 hours before the main episode of sleep.

### Digital Cognitive Behavioural Therapy for Insomnia (CBT-I) available

- [Sleepio](#) - Currently available free in some areas in the UK)
- [Sleepstation](#) – Available free on the NHS. The patient self-refers and then sees the GP who needs to approve the referral

### Recommended

- Overcoming Insomnia: A Cognitive-Behavioural Therapy Approach, Workbook (Treatments That Work) by Jack Edinger & Colleen Carney (2014)
- Overcoming Insomnia and Sleep Problems: A Self Help Guide Using Cognitive Behavioural Techniques by Colin Espie (2012)
- Say Goodnight to Insomnia: A Drug-Free Programme Developed at Harvard Medical School by Gregg Jacobs (2011)
- How to Beat Insomnia and Sleep Problems One Step at a Time: Using evidence-based low-intensity CBT by Kirstie Anderson (2018)

### Pathway for the pharmacological management of co-morbid insomnia in adults

Note: Melatonin, trazodone, mirtazapine and quetiapine are IMOC Amber 2 category – initiation by the sleep centre followed by maintenance prescribing in primary care. GPs are not expected to initiate these treatments but may be asked to take on prescribing in line with IMOC recommendations. Doxepin, agomelatine and vortioxetine are IMOC RED category (hospital only) – initiation and ongoing prescribing will be by the sleep service.

## Appendix 3 Patient cohorts appropriate for second line pharmacological therapies used in the management of co-morbid insomnia

| Drug                | Types of patients this is most useful for  | Cautions  |
|---------------------|--|---|
| <b>Trazodone</b>    | <ul style="list-style-type: none"> <li>• Sleep initiation and maintenance difficulties</li> <li>• Co-morbid nightmares</li> <li>• Co-morbid Restless Legs Syndrome</li> </ul>  | <ul style="list-style-type: none"> <li>• History of impulsive drug overdose</li> <li>• Prolonged QTc interval</li> </ul>  |
| <b>Mirtazapine</b>  | <ul style="list-style-type: none"> <li>• Sleep initiation and maintenance difficulties.</li> <li>• Co-morbid prominent nocturnal anxiety</li> </ul>  | <ul style="list-style-type: none"> <li>• Not helpful in nightmares</li> <li>• Can worsen restless legs syndrome</li> </ul>  |
| <b>Quetiapine</b>   | <ul style="list-style-type: none"> <li>• Severe insomnia, which has not responded to trazodone nor mirtazapine</li> <li>• Paradoxical insomnia</li> </ul>  | <ul style="list-style-type: none"> <li>• Prolonged QTc interval</li> <li>• Can use with other anti-psychotics in dose range for insomnia; total antipsychotic dose load to be calculated</li> </ul> |
| <b>Doxepin</b>      | <ul style="list-style-type: none"> <li>• Sleep initiation and maintenance difficulties.</li> <li>• When a liquid hypnotic is required e.g. PEG fed etc.</li> <li>• In patients with intellectual disabilities</li> <li>• In patients where there is no response to trazodone or mirtazapine, or where these are contraindicated</li> </ul> | <ul style="list-style-type: none"> <li>• Patient or carer needs to be able to make new doxepin solution each evening.</li> </ul>  |
| <b>Agomelatine</b>  | <ul style="list-style-type: none"> <li>• Insomnia with co-morbid depression.</li> <li>• If treatment failure on melatonin for REM Sleep Behavioural Disorder.</li> <li>• Consider in Smith Magenis Syndrome if lack of response to melatonin</li> </ul>  | <ul style="list-style-type: none"> <li>• Not in patients with hepatic dysfunction.</li> </ul>   |
| <b>Vortioxetine</b> | <ul style="list-style-type: none"> <li>• Depression with insomnia</li> <li>• Depression with REM Sleep Behavioural Disorder</li> <li>• Depression with sleep movement disorders</li> </ul>   |   |

Approval date: March 2023 Review date: March 2025 (or sooner if evidence or practice changes)

4

**Not to be used for commercial or marketing purposes. Strictly for use within the NHS**